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Abstract
Background: To create a self-reported, internet-based questionnaire for the assessment of suicide risk in children
and adolescents.
Methods: As part of the EU project ‘Suicidality: Treatment Occurring in Paediatrics’ (STOP project), we developed
web-based Patient Reported Outcome Measures (PROMs) for children and adolescents and for proxy reports by
parents and clinicians in order to assess suicidality. Based on a literature review, expert panels and focus groups of
patients, we developed the items of the STOP Suicidality Assessment Scale (STOP-SAS) in Spanish and English,
translated it into four more languages, and optimized it for web-based presentation using the HealthTrackerTM
platform. Of the total 19 questions developed for the STOP-SAS, four questions that assess low-level suicidality were
identified as screening questions (three of them for use with children, and all four for use with adolescents, parents
and clinicians). A total of 395 adolescents, 110 children, 637 parents and 716 clinicians completed the questionnaire
using the HealthTrackerTM, allowing us to evaluate the internal consistency and convergent validity of the STOP-SAS
with the clinician-rated Columbia Suicide Severity Rating Scale (C-SSRS). Validity was also assessed with the receiver
operating characteristic (ROC) area of the STOP-SAS with the C-SSRS.
Results: The STOP-SAS comprises 19 items in its adolescent, parent, and clinician versions, and 14 items in its
children’s version. Good internal consistency was found for adolescents (Cronbach’s alpha: 0.965), children
(Cronbach’s alpha: 0.922), parents (Cronbach’s alpha: 0.951) and clinicians (Cronbach’s alpha: 0.955) versions. A
strong correlation was found between the STOP-SAS and the C-SSRS for adolescents (r:0.670), parents (r:0.548),
clinicians (r:0.863) and children (r:0.654). The ROC area was good for clinicians’ (0.917), adolescents’ (0.834) and
parents’ (0.756) versions but only fair (0.683) for children’s version.
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Conclusions: The STOP-SAS is a comprehensive, web-based PROM developed on the HealthTrackerTM platform,
and co-designed for use by adolescents, children, parents and clinicians. It allows the evaluation of aspects of
suicidality and shows good reliability and validity.
Keywords: Suicidality, Adverse events, Adolescents, Children, Parents, Assessment, Scale
Background
According to the World Health Organization, ap-
proximately one million people commit suicide each
year worldwide [1]. The age range with the greatest
risk of suicidal behaviour is adolescence and early
adulthood [2, 3]. Lifetime prevalence rates in adolescents
are reported cross-nationally to be 19.8–24.0% for suicidal
ideation and 3.1–8.8% for suicide attempts [4].
Suicidality, however, is a complex behaviour with
many interrelated elements. It comprises the following
elements: suicidal ideation (thoughts about death, a wish
to be dead), suicide plans (thinking about ways of carry-
ing out a self-injurious behaviour that could result in
death), suicide communication or threats (transmitting
or expressing thoughts about or the intention of suicide,
either explicit or implicit), suicide behaviours involving
self-harm (self-injuries with no intent to die), and suicide
attempts (self-inflicted, dangerous behaviour with the
aim of dying but a non-fatal outcome) [4, 5].
The term ‘Medication-Related Suicidality’ (MRS) refers
to any suicide-related symptoms that are reported dur-
ing the period of treatment with a drug. In particular,
previous studies have shown a weak but significant risk
of self-harm and suicidal ideation in adolescents treated
with antidepressants [6, 7]. As a consequence, the as-
sessment of suicidality in both pre- and post-marketing
clinical trials of the various drugs developed by pharma-
ceutical companies has become a pressing issue. Other
instruments that evaluate suicidality include the Suicidal
Ideation Questionnaire Junior [8], the Suicidal Behav-
iours Questionnaire-Revised [9], the Sheehan Suicidality
Tracking Scale [10] and the Beck Suicide Ideation Scale
[11] among others. A key distinction between these
existing measures is that the majority of previous mea-
sures have been developed for use in adult patients and
almost exclusively have not been developed for web-
based completion. Most of them have been developed
for adult patients and are not web-based questionnaires.
There is a need to develop measures to specifically as-
sess suicidality in the child and adolescent populations
given the specific stresses they experience at this age.
Since suicidality remains a delicate topic, it can be ar-
gued that a proven web-based health monitoring plat-
form could be particularly useful in this population, as
they provide a space for honest responses to sensitive
topics.
Patient Reported Outcome Measures (PROMs) have
enabled patients to be more forthcoming in disclosing
information about subjective states of health to a clin-
ician, including suicidal ideation and behaviour [12].
PROMs include self/proxy assessments of outcomes and
experience of symptoms, functional status, patient
needs, and satisfaction with care [13–15].
The STOP project (Suicidality: Treatment Occurring in
Paediatrics; grant agreement number: 261411) is a re-
sponse to a specific research call made under the FP7 Co-
operation Work Program ‘HEALTH.2010.4.2-3: Adverse
drug reaction research’. The aim of the STOP project was
to develop and validate a comprehensive web-based mod-
ule for the assessment and monitoring of suicidality and
its mediators in children and adolescents using the
HealthTracker™ health monitoring platform.
In this study, which is part of the STOP project, we
describe the development of a self-reported, web-based
questionnaire for assessing suicide risk in children and
adolescents, which aimed specifically to capture the dif-
ferent elements of suicidality. The instrument, known as
the STOP Suicidality Assessment Scale (STOP-SAS),
consists of two self-report questionnaires (one for chil-
dren aged 8–11 years, one for adolescents 12–18 years)
and two parent-report and clinician-report question-
naires. The questionnaires were administered to a sam-
ple of adolescents, children, parents and clinicians and
validated against the C-SSRS. A secondary aim of the
present study was to identify a set of questions from the
STOP-SAS that assess low-level suicidality that could be
used for screening.
Methods
STOP Project
The checklist was developed as part of the EU FP7 pro-
ject—“Suicidality: Treatment Occurring in Paediatrics
(STOP study; www.stop-study.com)” [16]. The STOP pro-
ject aimed to develop a comprehensive web-based meth-
odology for the assessment and monitoring of suicidality
in children and adolescents. This study focussed on devel-
oping valid web-based suicidality measures (in multiple
languages) for children and adolescents on the Health-
TrackerTM (a health monitoring platform), for use in
assessing suicidality, detecting impact of medication on
suicidality, and suicidality related risk and resilience fac-
tors. The participants, parents and clinicians completed a
Flamarique et al. BMC Pediatrics  (2016) 16:213 Page 2 of 13
wide-ranging battery of scales in order to report the symp-
tom experience (both related to suicidality and symptoms
generally), medication adherence and compliance, and
quality of life. This manuscript describes specifically the
development of the STOP-SAS.
HealthTrackerTM
HealthTrackerTM (https://www.healthtracker.co.uk), a
multi-modal real time web-based e-health monitoring
tool, is suitable for risk stratification and monitoring and
post-marketing surveillance of medication as it can cap-
ture longitudinal data about behaviour, emotions, side-
effects, cognitive functions, quality-of-life of both the
child/adolescent and family along with details of all
medication used as well as medication adherence and
compliance [17]. The HealthTrackerTM optimises clin-
ician time by helping to profile young people before be-
ing seen in clinic and is used to monitor patient-centred
outcomes as part of clinical treatment.
Ethical Approval
All centres had ethical approval for the study from their
local committees using the standardised protocol. The
UK (London) was the lead site for the STOP Project and
the ethics details were: REC Reference Number 13/LO/
0401; Kent Research Ethics Committee and Institute of
Psychiatry, King’s College London Research and Devel-
opment Office.
Item Generation and Preliminary Scale Development
The development of the instruments followed the FDA
recommendations for Patient Reported Outcome Mea-
sures (PROMS) [15]. The initial items of the STOP-SAS
were developed via consultation of respective publica-
tions in the literature and existing scales, and by consid-
ering the aspects assessed by the C-SSRS [18]. The
schema developed by Silverman [19], which differenti-
ates between the presence or absence of suicidal intent,
and between the presence or absence of injury, was also
considered [15]. Suicidal behaviours with no intent to
die include those in which the person wishes to use the
appearance of killing him/herself for other purposes
(e.g., seeking help, punishing others, receiving attention,
regulating negative mood) while suicidal behaviours in-
volving an undetermined intent to die are those in which
the intention is unknown (e.g., unconsciousness, dissoci-
ation, being under the influence of drugs, being delu-
sional, or reluctance to admit to the intent to die) [19].
Other scales such as the Suicidal Ideation Questionnaire
(Junior High School Version) [8], as well as expert opin-
ions were also taken into consideration in order to de-
velop the first version of the scale. The first version of the
STOP-SAS, which included 12 items, was developed sim-
ultaneously in English and Spanish and was discussed
thoroughly with a panel of European experts from Spain,
UK, France, Italy and Germany.
Focus Groups
Patients’ understanding of the initial STOP-SAS scale
was assessed through cognitive interviewing in eight
focus groups with children, adolescents and parents.
This qualitative research tool was used to ensure under-
standing of the concepts contained in the items. Groups
were small, consisting of three or four individuals re-
cruited at the outpatient unit of the Child and Adoles-
cent Psychiatry Department of the Hospital Clinic of
Barcelona. Participants and their parents completed an
assent and consent form. The Hospital’s Ethics Commit-
tee approved the study. With the permission of partici-
pants, all the group sessions were video-recorded.
Participants were asked a combination of standard
probes and on-the-spot probes (verbal probing method)
[20]. After each focus group the content of the video-
tapes was transcribed. The transcripts were analyzed
using the thematic analyses and cut-and-paste method,
and a detailed summary report was written regarding
each focus group [21, 22]. Discussions between experts
from UK and Spain were held to produce the final ver-
sion of the questionnaire. A clinician’s version was also
created based on the parents’ and adolescents’ versions.
The final versions of the questionnaires in English and
Spanish were reviewed by a professional translator for
comparability of the questions in the two languages. The
STOP scientific advisory board also suggested some
changes that were implemented by the expert panel and
authorized by the consortium. The English scales were
then translated into German, Dutch, French and Italian,
and then back-translated into English. Discussions be-
tween experts from each country were held to ensure
that the meaning of each statement remained culturally
sensitive, and the questionnaires were then finalized. A
flow chart of the creation of the STOP-SAS is shown in
Fig. 1. The definitive questionnaires were then uploaded
onto HealthTracker™, an online multimedia platform with
a suite of questionnaires for monitoring health that allow
accurate measurements of change across a wide range of
symptoms, adverse events, psychological functions and
quality of life. It was developed as a multi-informant sys-
tem for use by children, adolescents, parents, teachers, cli-
nicians and researchers and allows for questionnaires to
be presented in a user-friendly manner, assisted by audio
recordings for those with hearing problems [16, 17]. The
system also allows the clinician to assign the question-
naires taking into consideration the mental age of the re-
spondent. This flexibility is important, especially for those
with intellectual or learning disabilities. For severely im-
paired children, one must rely on parent and clinician
proxy questionnaires [17].
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Psychometric properties of the scale
To carry out the evaluation of the STOP-SAS’s psy-
chometric properties (internal consistency and conver-
gent validity), the questionnaires were completed
online via the HealthTracker™ system by a sample of
patients (adolescents and children), their parents and
clinicians from the various participating centres.
These centres were specifically selected as part of a
consortium based on expert child and adolescent
psychiatric practice. There were 2 sites in Spain
(Madrid and Barcelona), 2 sites in the UK (London
and Dundee), one site in Italy (Cagliari), 3 sites in
France (2 hospitals in Paris and one in Montpellier),
2 sites in Germany (Ulm and Mannheim) and 2 further
sites in the Netherlands (Groningen and Nijmegen). The
clinicians completing the questionnaires were the expert
psychiatrists who worked with the young person in the
clinical setting.
Fig. 1 Flow chart summarizing the development of the scales
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A total of 763 parents/legal tutors of patients from the
different centres signed an informed consent to partici-
pate in the study. Of these 763 families, 576 included an
adolescent (age between 12 and 17 years old), 187 a
child (age between 8 to 11 years old). In some of the
cases only parents or clinicians answered the question-
naires due to intellectual or learning disabilities of the
patient. For the assessment of convergent validity, the C-
SSRS was used. Validity was also assessed using the re-
ceiver operating characteristic (ROC) analyses. For this
purpose we used the gold standard (C-SSRS) total score
and created a dichotomous variable: if the total score
was other than “zero” the value was “1” (suicidality is
present) and it was “zero” the value was “0”(suicidality is
not present). The C-SSRS is a clinician-administered
questionnaire that assesses suicidal ideation and suicidal
behaviours based on several ordinal items. Suicidal be-
haviours include suicide attempts and completed sui-
cides, as well as any preparatory act with a view to
attempting suicide [23].
Screening questions
Since the investigators, the Scientific Advisory Board,
and Ethics Committees recommended reducing the
burden of answering a large number of questions re-
garding suicidality in non-suicidal subjects, the ex-
perts then identified a set of four questions from the
STOP-SAS that could be used as screening questions
(three of them for use with children, and all four for
use with adolescents, parents and clinicians). These
items were selected because they assess low-level sui-
cidality. Using data from a subsample of patients who
responded to all the questions, we checked that if a
patient or parent answered “never” to all the screen-
ing questions they also answered “never” to all the
remaining questions of the STOP-SAS. This sub-
sample comprised a total of 53 children, 93 adoles-
cents and their parents and clinicians who answered
all the questions. A negative answer to all the screen-
ing questions would then be considered as a total
score of “zero” for the entire STOP-SAS, while one
positive answer to any of these questions would auto-
matically require the participant to complete the en-
tire questionnaire. Experts ensured that the set of
four screening questions for adolescents, parents and
clinicians, and the three for use by children fulfilled
this criterion.
Data analysis
Descriptive Statistics
Descriptive statistics (percentages, means and standard
deviations) were used to summarize the results.
Psychometric Properties of the STOP-SAS
A one-way between-groups multivariate analysis of vari-
ance was performed to compare the mean total scores
between groups (parents, clinicians and children or ado-
lescents). A total score was calculated by adding up the
values of the response options (0 to 5 for adolescents,
parents and clinicians and from 0 to 3 for children). The
total scores were then transformed to a range from 0 to
100, so children’s scores were comparable to parents’
and clinicians’. The Mauchly’s Test of Sphericity was
used to evaluate Sphericity. The Greenhouse-Geisser
correction was used if the assumption of sphericity had
been violated. A t-test was then applied for post-hoc
analysis (t-test with Bonferroni correction for multiple
comparisons). Internal consistency was estimated using
Cronbach’s alpha coefficient. Pearson’s correlation was
used to assess correlation between respondents and con-
vergent validity between the STOP-SAS and the C-SSRS.
A correlation coefficient of >/= .10 represents a weak as-
sociation, one of >/= .30 a moderate correlation, and
one of >/= .50 or larger a strong correlation [24]. Valid-
ity was also assessed using the receiver operating charac-
teristic (ROC) analyses using the C-SSRS as the gold
standard. Cut off scores, sensitivity, and specificity were
also computed. All statistical analyses were performed
using the SPSS20.0 software package.
Screening questions analyses
In order to statistically test the predictive power of the
screening questions on the overall score we created two
variables: one was obtained by the sum of the first four
items scores (Or three for the children’s version) and the
other was the sum of the scores of all the rest of the
questions. Pearson’s correlation was used to assess cor-
relation between these two new variables. Moreover,
these two variables were transformed in two dichotom-
ous variables called “Screening-questions” and the
“STOP-SAS-RestQ”. These variables might have two
values: “0” if the sum of all the items which compose the
variable is zero and “1” for all the other possible scores.
We calculated the Kappa measure of agreement between
the “Screening-questions” and “STOP-SAS-RestQ”.
Results
Focus Groups
 Adolescents’, parents’ and clinicians’ questionnaires
Three focus groups were created, each comprising
three or four adolescents aged between 12 and 17
years old (total n = 10). Sixty per cent of the total
sample was female, and the primary diagnoses were
anorexia nervosa (n = 5), major depression (n = 3) and
anxiety disorders (n = 2). The mean age of the sample
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was 15.60 ± 1.07 years. The focus group sessions
lasted between 70 and 85 min. Overall, adolescents
expressed their preference for a computer-based scale
rather than a printed version. The recall period sug-
gested by participants was 1 month. They also sug-
gested that some items from the STOP-SAS should
be re-worded, although none needed to be removed.
They thought that being asked about suicide was im-
portant and necessary for suicide prevention. A num-
ber of different response scales were tested (including
7-point and 6-point Likert scales) in order to deter-
mine the optimal number of response options. Partici-
pants preferred six options.
Five parents of the adolescents also participated in two
focus groups for parents. They understood all the items
included in the instrument. They suggested that two
questions which included concepts about “hurting your-
self” and “killing yourself” in the same item should be
presented separately, and so two new items were added.
The third version of the instrument for adolescents,
parents and clinicians thus consisted of 14 items.
 Children’s questionnaire
The first version of the questionnaire for children be-
tween 8 and 11 years was a simplified version of the ver-
sion for adolescents. Four items were removed, and it
was decided to use a 4-point Likert-type response. Some
items and the response options were re-worded using
more age-appropriate vocabulary, while other statements
were shortened. The first version thus consisted of ten
questions. This version was presented to the three focus
groups comprising three children each, aged between 8
and 11 years. The focus groups lasted between 30 and
55 min. The children understood all questions, but some
of them were re-worded as children had some difficulties
in differentiating them. They also suggested including
some examples to make them easier to understand. The
recall period was modified for children, with ‘1 month’
being changed to ‘over the last few days’. The second
version of the children’s instrument also consisted of ten
items.
Final agreement on scale formats between experts
 STOP-SAS Adolescent’, Parent’ and Clinician’
versions
The revised adolescent version was reviewed by the
UK and Spanish experts, who agreed to add a further
two items about suicide plans, namely ‘preparatory acts’
and ‘reasons’ in order to include all the components of
suicidality and to map the C-CASA algorithm. The
resulting versions designed for adolescents, parents and
clinicians had five items referring to suicidal ideation, six
items to suicidal behaviour, four to suicide plans and
one to suicide communication. On the advice of the
STOP Scientific Advisory Board, we added three items
referring to suicidal ideation, as they felt that the scale
required some questions assessing low-level suicidality.
Thus, the final versions for adolescents, parents and cli-
nicians consisted of 19 questions. All three versions in-
cluded the same items and the same content, with a
slight change in the questions depending on the re-
spondent to make it clear that the questions were about
the child/adolescent. The panel of experts decided to
add a stand-alone item to ask about potential lethality to
the clinician’s version. This question was only visible if
there was a positive answer to behaviour and there were
no injuries associated to that behaviour. This item was
not considered a part of the questionnaire and it will not
be considered in the analysis. Table 1 shows the different
items that comprise the instrument.
 STOP-SAS Children’s version
The instrument for children comprised five items on
suicidal ideation, two on suicide plans and three on sui-
cidal behaviour. Two new items about suicidal behaviour
were added to the children’s version: ‘aborted attempt’
and ‘undetermined suicide behaviour’, in order to cover
the C-CASA algorithm. The children’s version thus had
12 items. Based on the advice of the STOP Scientific
Advisory Board, we added two items capturing low-level
suicidality for children, making the final version 14 ques-
tions long. Items included in the children’s version are
shown in Table 1.
An example of a couple of questions from the parent
version of the STOP-SAS is shown in Fig. 2.
Psychometric properties of the STOP-SAS questionnaires
 Adolescent’, Parent’ and Clinician’ questionnaires
A total of 395 adolescents, 637 parents completed the
questionnaires, together with 716 questionnaires com-
pleted by clinicians. The adolescent and parent sample
(n = 576), were all recruited from child and adolescent
psychiatric outpatient settings in Spain (n = 191, 33.2%),
United Kingdom (n = 155, 26.9%), Italy (n = 103, 17.9%),
the Netherlands (n = 45, 7.8%), France (n = 45, 7.8%),
and Germany (n = 37, 6.4%). Females comprised 51.4%
of the sample, and the mean age was 14.94 ± 1.65 years.
The main diagnoses and treatments are shown in
Table 2.
The STOP-SAS for adolescents, parents and clinicians
showed adequate internal consistency. The best cross-
informant correlation was found between clinicians and
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adolescents, although the correlation between parents
and adolescents, and parents and clinicians was also
high. Data regarding internal consistency and correlation
between informants are shown in Table 3.
In the one-way between-groups multivariate analysis of
variance, the mean total score (range 0 to 100) for adoles-
cents, parents and clinicians was the dependent variable.
The independent variable was the version of the question-
naire. Results showed a significant difference between
groups in the mean total score (F2,322 = 51.689.079, p <
0.001). It also showed a pattern in which adolescents pre-
sented with the highest score, parents the lowest score
and clinicians in-between. Post-hoc pairwise comparisons
between adolescents and parents and adolescents and
clinicians were then performed (Bonferroni adjusted p
value = 0.016). The mean total score of the STOP-SAS for
adolescents (16.13 ± 19.93) was significantly higher than
the total score for parents’ reports (7.01 ± 10.67; t =10.14
p < 0.001). It was also higher (17.44 ± 20.33) than the total
score for clinicians’ report (11.52 ± 14.66; t = −8.72 p <
0.001). A strong correlation was found between the
STOP-SAS total score for clinicians and the clinician-
rated C-SSRS (r = 0.863, p < 0.001). The correlation with
the C-SSRS was also strong for the adolescents’ SAS ver-
sion (r = 0.670, p < 0.001) and the parents’ version (r =
0.548, p < 0.001). Regarding results from the ROC analysis,
the accuracy of the clinicians’ version to identify suicidal
ideation and behaviours (suicidality) was excellent
Fig. 2 Example from the parent STOP-SAS questionnaire: statement, question and response options
Table 1 Items of the different versions of the STOP-SAS instrument
Item Name Adolescents’
version
Parents’
version
Clinicians’
version
Children’s
version
Thoughts of being dead or what it would be like to be dead X X X
I feel life is not worth living X X X X
Thoughts of hurting myself X X X X
Thoughts about ending my life X X X X
Thoughts that no one would care if I lived or died X X X X
Thoughts of harming self to feel better X X X X
Thoughts to end life but would not act X X X X
I have little doubt (am certain) about wanting to kill myself; X X X X
I have done something to hurt myself X X X
I cannot control my thoughts about killing myself X X X
I have started to work out the details to end my life X X X X
Worried about being judged socially if I hurt myself X X X
I have made preparations to kill myself X X X X
Hurt myself WITHOUT intent X X X X
Hurt myself WITH intent X X X X
I have hurt myself but I am not sure if I want to end my life X X X X
Attempt interrupted by others X X X X
I was about to do something to hurt/kill myself but stopped myself just before
I initiated it
X X X X
I planned to hurt or kill myself X X X
Can you rate the potential lethality of the behaviour? X a
a Item answered by clinicians only when there is a positive answer to a suicidal behaviour
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compared with the C-SSRS. The accuracy of the adoles-
cents’ version was good, and fair for the parents’ version.
Results from the ROC analysis are showed in Table 4.
 Children’s questionnaire
A total of 110 children of 187 being seen in centres in
Spain (n = 58, 31%), United Kingdom (n = 42, 22.5%),
France (n = 33, 17.6%), Italy (n = 27, 14.4%), the
Netherlands (n = 24, 12.8%) and Germany (n = 3, 1.6%)
answered the questionnaires. Only 21.9% of the subjects
were female, and the mean age was 9.86 ± 1.12 years.
Clinical and treatment characteristics of the sample are
shown in Table 2. The STOP-SAS for children showed
good internal consistency. The correlation between in-
formants was good between clinicians and children and
between parents and clinicians but lower between par-
ents and children (Table 3).
In the one-way between-groups multivariate analysis
of variance, no significant differences were observed in
the mean total scores (range 0–100) between children,
parents and clinicians (F2,102 = 0.367, p = 0.694). A strong
correlation was found between the STOP-SAS total
score for children and the clinician-rated C-SSRS scores
(r = 0.654, p < 0.001). Results for the children’s version
regarding the ROC analysis against the C-SSRS were fair
(Table 4).
Screening questions
The correlation between the two variables created by
adding up the screening questions and the rest of the
questions, was very high for the four screening questions
(r = 0.906, p < 0.001) and the three screening questions
for children (r = 0.891, p < 0.001). For the two dichotom-
ous variables created (Screening-questions and the
STOP-SAS-RestQ) for adolescents, parents and adoles-
cents together, the Kappa value was 0.843. For the same
variables for children, the Kappa value was 0.723.
The overall estimation of agreement between the
Screening-Questions and the rest of the STOP-SAS scale
Table 2 Clinical and demographic characteristics of participants
in the validation study
Participants Adolescents
n = 576
(%)a
Children
n = 187
(%)a
Diagnoses DSM-IV-TR*
Eating disorder 65 (6.1) 0
Major Depressive Disorder (MDD) 258 (24) 16 (3.9)
Attention Deficit Hyperactivity
Disorder (ADHD)
153 (14.3) 127 (30.6)
Conduct Disorder/Oppositional
Defiant Disorder (CD/ODD)
89 (8.3) 60 (14.5)
Bipolar Disorder 39 (3.6) 6 (1.4)
Schizophrenia and Other
Psychotic Disorders
36 (3.4) 0
Anxiety Disorders 129 (12) 35 (8.4)
Pervasive Developmental
Disorders
114 (10.6) 67 (16.1)
Tic Disorders 25 (2.3) 13 (3.1)
Substance Related Disorders 14 (1.3) 0
Mental Retardation 55 (5.1) 35 (8.4)
Learning Disorders 20 (1.9) 12 (2.9)
Other Disorders 76 (7.1) 44 (10.6)
Pharmacological treatment
Antipsychotics 367 (41) 143 (48)
Antidepressants 265 (29.6) 22 (7.4)
Stimulants 60 (6.7) 68 (22.8)
Mood stabilizers and Lithium 46 (5.1) 10 (3.4)
Benzodiazepines 36 (4) 1 (0.3)
Other psychiatric pharmacological
treatments
56 (6.3) 35 (11.7)
Non-psychiatric pharmacological
treatments
64 (7.1) 19 (6.6)
No pharmacological treatment 68 (11.08)b 19 (10.16)b
* DSM-IV-TR = The Diagnostic and Statistical Manual of Mental Disorders.
Fourth edition, text revised
a Percentage considering the total number of medications and diagnoses
b Number of patients and percentage considering total number of patients
Table 3 Internal consistency and Cross-informant correlation coefficients
Psychometric properties: Internal consistency. Cross-Informant correlation coefficients (Pearson’s r)
Cronbach’s alpha PARENTS ADOLESCENTS CHILDREN
CLINICIANS 0.955 r = 0.591 r = 0.765 r = 0.640
(n = 716) p < 0.001 p < 0.001 p < 0.001
ADOLESCENTS 0.964 r = 0.560
(n = 395) p < 0.001
CHILDREN 0.922 r = 0.473
(n = 110) p < 0.001
PARENTS 0.951
(n = 637)
Flamarique et al. BMC Pediatrics  (2016) 16:213 Page 8 of 13
(the STOP-SAS-RestQ) showed that in 96.4% of the
cases, if an adolescent, parent or clinician answered
“never” to all the screening questions they also answered
“never” to all the remaining questions. There was some
inconsistency between the screening questions and the
rest of the scale in seven adolescents, but after checking
their specific answers and a discussion with the experts’
panel, they were classified as non-suicidal. The estima-
tion of agreement between the three screening questions
for children and the rest of the questionnaire showed
similar results with only two cases that showed incon-
sistency. In this case reviewing their answers showed
they were not suicidal. Data are shown in Table 5.
Discussion
The present study describes the development and valid-
ation of the STOP-SAS, a web-based PROM measuring
suicidality on the HealthTrackerTM system using the
FDA recommendations for outcome measure develop-
ment. These initial psychometric validation data suggest
that it is a reliable and valid instrument for assessing sui-
cidality in children and adolescents. It also shows in all
its versions, a significant correlation with the clinician-
rated C-SSRS.
Adolescents in the focus groups clearly expressed
the view that it was important to ask about suicidal-
ity. Suicide prevention is important in adolescents
[25] and screening for suicidality in high school has
been shown to be a safe component of youth suicide
prevention programs [26]. It is worth noting that the
adolescents said that they preferred a web-based
questionnaire to a printed version, as they would be
able to discuss their internal experiences more openly.
Previous studies have reported that the use of com-
puters increase the sense of privacy and may yield an-
swers that are less socially desirable but more sincere
[27, 28].
Due to development-related needs, the number of
response options in the children’s questionnaire was re-
duced to four. Previous studies have recommended the
use of between three and five responses for children be-
tween 8 and 11 years [29]. The recall period for children
was modified from “over the last month” to “over the
last few days”, because shorter recall periods and “here-
and-now” type questions are preferable for this age
group [30].
Psychometrically, internal consistency was good for all
versions of the STOP-SAS. Agreement between infor-
mants (adolescents, parents and clinicians) regarding ad-
olescents was good. This result contrasts with those of
some studies that have reported low concordance be-
tween parents and adolescents when interviewed about
psychopathology or suicidal ideation [31–33]. However,
one previous study showed that the agreement between
adolescents and parents was higher concerning recent
suicide attempts than concerning attempts in the past
[34]. Nevertheless, the mean total STOP-SAS score for
adolescents was significantly higher than for parents.
These findings corroborate those of previous studies that
have reported under-recognition of suicidal ideation and
other internalizing symptoms by parents compared to
adolescents [31, 33, 35]. On the other hand, clinicians’
mean total scores were in-between parents’ and adoles-
cents’ scores. These results suggest that adolescents
Table 4 Receiver Operating Characteristics between the STOP-SAS and the C-SSRS
STOP-SAS cut off scores Sensitivity
(%)
Specificity
(%)
ROC Area SE Asymptotic Normal
(95% CI)
Adolescents’ version ≥4.78 80.5 78.8 0.834 0.022 0.791 0.878
Children’s version ≥0.52 60 71.2 0.683 0.056 0.574 0.792
Parents’ version ≥0.43 72.7 69.8 0.756 0.020 0.716 0.796
Clinicians’ version ≥0.43 88.5 85.4 0.917 0.012 0.893 0.940
ROC Receiver Operating Characteristics, SE Standard Error, CI Confidential Interval
Table 5 Screening questions compared to the rest of the STOP-SAS questionnaire
Adolescents Screening-questions = 0 Screening-questions = 1 total
The STOP-SAS-RestQ = 0 n = 185 (96.4%) n = 20 n = 205
The STOP-SAS-RestQ = 1 n = 7 n = 137 n = 144
total n = 192 n = 157 n = 349
Children total
The STOP-SAS-RestQ = 0 n = 39 (95.1%) n = 3 n = 42
The STOP-SAS-RestQ =1 n = 2 n = 9 n = 11
total n = 41 n = 12 n = 53
Flamarique et al. BMC Pediatrics  (2016) 16:213 Page 9 of 13
disclose more easily information regarding suicidality to
clinicians rather than to their parents.
Agreement between clinicians and children and
between clinicians and parents was good, but lower be-
tween parents and children. This latter finding is con-
sistent with previous research that has assessed
psychopathology and parent and child agreement and
has reported low cross-informant correlations, especially
for internalizing symptoms [36–38]. No differences were
found between the mean total scores of children, parents
and clinicians.
There was a strong correlation between the
clinician-rated C-SRSS total score and the clinicians’,
parents’, adolescents’, and children’s STOP-SAS total
scores. Moreover, results from the ROC analysis were
excellent for the clinician version and good for ado-
lescent and parent versions compared with the gold
standard (C-SSRS). However, results were only fair for
the children’s version. These findings suggest that the
STOP-SAS is a valid instrument for assessing suicidal-
ity in adolescents, using self-reports or proxy reports
by parents and clinicians. The interpretation of the
results for the children’s version must be more cau-
tious as it is possible that some children who are sui-
cidal fail to report it, due to recall bias related to
their memory capacity [38]. Other possible explana-
tions for these results include the child misunder-
standing the question or not feeling comfortable
disclosing this information to a stranger. Nevertheless,
some authors have suggested that all sources of infor-
mation regarding suicidality in children should be
considered when exploring child suicidality, as it is
not clear who is the best reporter of suicidality. As
parents may not detect suicidality in all cases and
screening children may be necessary [38].
There is no data presented in this study on a test-
retest of the measure. The test-retest reliability method
was decided against, because we expect changes in sui-
cidality even during short time-windows. The scores of
items in the STOP-SAS would change with change in
suicidality and hence test-retest was deemed inappropri-
ate. It has been previously reported that for remitting
and relapsing or episodic diseases, test retest reliability
may be difficult or impossible to establish [12]. Previous
studies with children and adolescents have found low
test-retest reliability for scales measuring psychiatric
symptoms or suicidality [39, 40]. This could be explained
by the fact that symptoms such as suicidality and de-
pression are expected to change over time, notably espe-
cially in young children [41]. In addition, in middle
childhood (7–12 years old), memory capacity is still de-
veloping and retrospective questions may be a problem
as children are prone to construct scripts of familiar
routine if they do not remember the event [42].
One limitation of the development of the question-
naires is that focus groups were only held in Spanish,
and the translations into English, French, Italian, Dutch
and German were examined only by experts. Another
limitation is that test-retest reliability has not been in-
cluded as part of the psychometric properties of the new
instruments due to the fact that suicidality is expected
to change with time, especially in young children [41].
Another limitation is the sample size used for the valid-
ation of the children’s version that is quite small com-
pared to the other groups, and that this version is less
accurate in identifying suicidal ideation and behaviour
(suicidality) compared with the C-SSRS. More reliable
and valid results would be generated by including a lar-
ger sample of children with diverse degrees of suicidality;
however the frequency of suicidal ideation or behaviour
in children is very low and, therefore, it is difficult to re-
cruit a sample with diverse degrees of suicidality. Given
the population, one must acknowledge that external val-
idity cannot be assumed across the adolescent popula-
tion, but it does offer insight into the complex child and
adolescent psychiatric population where suicidality is ar-
guably more likely.
The STOP-SAS has a number of major strengths. Its
development complies with the recommendations of the
FDA for PROMs [12]; it is based on consultations with
expert panels and the study of focus groups; it is avail-
able in different languages; and it obtains data from dif-
ferent sources, the patient, the parent and the clinician.
On the advice of the Scientific Advisory Board, the
STOP-SAS includes some questions about suicidal idea-
tion assessing low-level suicidality such as “I have
thoughts about being dead or what it would be like to be
dead.”, “I feel life is not worth living.” “I have thoughts
that no one cares if I lived or died, that others would be
better off if I were dead.” Some authors have suggested
that the C-SSRS is incomplete in assessing passive sui-
cidal ideation [43, 44] and it may be potentially danger-
ous to ignore this type of thoughts. Further, the
correlations with the clinician-rated Columbia-SSRS are
strong. In addition, the STOP-SAS is available on the
web-based HealthTrackerTM system, allowing scoring in
real-time and providing an automated alerting system
for suicide prevention programmes and pharmacovigi-
lance. Moreover, the STOP-SAS includes questions about
thoughts of self-harm that are not part of the C-SSRS. It
could be argued that it may be important to ask about
these thoughts for clinical practice and prevention of self-
harm and acts of suicidal behaviours [44]. In addition, the
questionnaire includes questions that measure the schema
developed by Silverman [19] which differentiates between
the presence or absence of suicidal intent, and between
the presence or absence of injury, and adds a question to
assess a third category “Undetermined Suicide-Related
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Behaviour: is a self-inflicted, potentially injurious behav-
iour where intent is unknown.
Conclusions
In conclusion, the data shows that the STOP-SAS ques-
tionnaire is a comprehensive, rapid-to-use, web-based
measure of suicidality for children and adolescents,
using self and proxy measures from parents and clini-
cians. It has shown good internal consistency and good
convergent validity with the C-SSRS. The children’s ver-
sion shows good internal consistency and a good correl-
ation with the C-SSRS; however the Area Under the
Curve in the ROC analysis showed fair results when
compared against the C-SSRS. An exploratory factor
analysis and confirmatory factor analysis will now be
performed to determine how many factors comprise the
newly developed instruments. In addition, the STOP-
SAS will be tested under the auspices of the STOP pro-
ject in longitudinal paediatric observational cohorts in-
volving children and adolescents taking atypical
antipsychotics (risperidone, aripiprazole), children and
adolescents with depression (treated with fluoxetine,
non-pharmacological/cognitive behaviour therapy), chil-
dren and adolescents with asthma or respiratory allergies
(treated with montelukast or other medications) and a
group of normal children and adolescents without psy-
chopathology. Results from these trials will help to de-
fine how the HealthTrackerTM-based STOP-SAS can
best be used in registration trials, pharmacovigilance,
and epidemiological and observational studies in the
future.
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